Cancer

Oncocyte Reports First Quarter 2023 Financial Results

Nearing Manufacturing Start Up of First Kitted ProductIRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision…

1 year ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy…

1 year ago

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

Cash on Hand of $15.5M Expected to Support Completion of the CAReS Trial and Operations into Second Half of 2024SOLANA…

1 year ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

Company maintains strong cash position of $231.6 millionSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…

1 year ago

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins…

1 year ago

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE…

1 year ago

Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis

-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-WALTHAM, Mass.,…

1 year ago

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion…

1 year ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to…

1 year ago

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists…

1 year ago